TW200621803A - Anti-a33 antibody - Google Patents

Anti-a33 antibody

Info

Publication number
TW200621803A
TW200621803A TW094130541A TW94130541A TW200621803A TW 200621803 A TW200621803 A TW 200621803A TW 094130541 A TW094130541 A TW 094130541A TW 94130541 A TW94130541 A TW 94130541A TW 200621803 A TW200621803 A TW 200621803A
Authority
TW
Taiwan
Prior art keywords
antibody
ferm
deposition number
fragment
functional fragment
Prior art date
Application number
TW094130541A
Other languages
English (en)
Other versions
TWI359154B (zh
Inventor
Shiro Kataoka
Takafumi Tomura
Noriko Otani
Original Assignee
Kirin Brewery
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kirin Brewery filed Critical Kirin Brewery
Publication of TW200621803A publication Critical patent/TW200621803A/zh
Application granted granted Critical
Publication of TWI359154B publication Critical patent/TWI359154B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW094130541A 2004-09-06 2005-09-06 Anti-a33 antibody TW200621803A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2004259090 2004-09-06

Publications (2)

Publication Number Publication Date
TW200621803A true TW200621803A (en) 2006-07-01
TWI359154B TWI359154B (zh) 2012-03-01

Family

ID=36036478

Family Applications (1)

Application Number Title Priority Date Filing Date
TW094130541A TW200621803A (en) 2004-09-06 2005-09-06 Anti-a33 antibody

Country Status (10)

Country Link
US (2) US7579187B2 (zh)
EP (2) EP2145954A1 (zh)
JP (2) JP4088655B2 (zh)
KR (1) KR100918746B1 (zh)
CN (1) CN101010427B (zh)
AU (1) AU2005280975B2 (zh)
CA (1) CA2579391C (zh)
HK (1) HK1105993A1 (zh)
TW (1) TW200621803A (zh)
WO (1) WO2006028197A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207304B2 (en) 2006-10-19 2012-06-26 Csl Limited Antibody antagonists of interleukin-13 receptor α1
US7883705B2 (en) 2007-02-14 2011-02-08 Kyowa Hakko Kirin Co., Ltd. Anti FGF23 antibody and a pharmaceutical composition comprising the same
MY149546A (en) 2007-11-02 2013-09-13 Novartis Ag Improved nogo-a binding molecules and pharmaceutical use tereof
EA026990B1 (ru) 2007-11-07 2017-06-30 Селлдекс Терапьютикс Инк. Антитела, связывающиеся с человеческой клеткой dec-205
AU2009268025B2 (en) 2008-07-08 2014-07-31 Geneuro Sa Therapeutic use of specific ligand in MSRV associated diseases
EP2917236A2 (en) * 2012-11-06 2015-09-16 MedImmune, LLC Combination therapies using anti-pseudomonas psl and pcrv binding molecules
AU2013370171B2 (en) * 2012-12-28 2018-09-13 Precision Biologics, Inc. Humanized monoclonal antibodies and methods of use for the diagnosis and treatment of colon and pancreas cancer
EP2777714A1 (en) 2013-03-15 2014-09-17 NBE-Therapeutics LLC Method of producing an immunoligand/payload conjugate by means of a sequence-specific transpeptidase enzyme
JP6895890B2 (ja) * 2015-02-10 2021-06-30 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊ 抗体
CN110540591A (zh) * 2019-08-09 2019-12-06 无锡傲锐东源生物科技有限公司 一种抗糖蛋白A33（Glycoprotein A33）单克隆抗体及其免疫检测应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5851526A (en) 1985-04-19 1998-12-22 Ludwig Institute For Cancer Research Methods of treating colon cancer utilizing tumor-specific antibodies
US5431897A (en) 1985-04-19 1995-07-11 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
EP0199141A3 (en) * 1985-04-19 1988-07-20 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancer
US5160723A (en) 1985-04-19 1992-11-03 Sloan-Kettering Institute For Cancer Research Method of imaging colorectal carcinoma lesion and composition for use therein
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
NZ226694A (en) 1987-10-28 1994-04-27 Oncogen Human immunoglobulin produced by recombinant dna techniques
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2128544A1 (en) * 1992-12-10 1994-06-23 Celltech Therapeutics Limited Humanised antibodies directed against a33 antigen
US6307026B1 (en) * 1992-12-10 2001-10-23 Celltech Limited Humanized antibodies directed against A33 antigen
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
WO2001030393A2 (en) * 1999-10-22 2001-05-03 Ludwig Institute For Cancer Research Methods for reducing the effects of cancers that express a33 antigen using a33 antigen specific immunoglobulin products
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US6643550B2 (en) * 2000-12-15 2003-11-04 Cardiac Pacemakers, Inc. Multi-polar connector
JP2004259090A (ja) 2003-02-27 2004-09-16 Toshiba Corp 情報処理装置および情報処理方法
US7432359B2 (en) * 2004-09-06 2008-10-07 Kirin Pharma Kabushiki Kaisha Anti-A33 antibody
JP4976741B2 (ja) * 2006-05-16 2012-07-18 株式会社東芝 平面アンテナ

Also Published As

Publication number Publication date
JP4088655B2 (ja) 2008-05-21
TWI359154B (zh) 2012-03-01
US20090299039A1 (en) 2009-12-03
US20070141054A1 (en) 2007-06-21
AU2005280975A1 (en) 2006-03-16
JP2008138004A (ja) 2008-06-19
HK1105993A1 (en) 2008-02-29
KR20070088570A (ko) 2007-08-29
EP1801208A1 (en) 2007-06-27
EP2145954A1 (en) 2010-01-20
US7579187B2 (en) 2009-08-25
JPWO2006028197A1 (ja) 2008-05-08
CA2579391C (en) 2010-10-26
WO2006028197A1 (ja) 2006-03-16
CN101010427A (zh) 2007-08-01
CN101010427B (zh) 2011-07-27
CA2579391A1 (en) 2006-03-16
KR100918746B1 (ko) 2009-09-24
EP1801208A4 (en) 2009-04-01
AU2005280975B2 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
TW200621803A (en) Anti-a33 antibody
MY145073A (en) Anti-glypican 3 antibody
MX2009003838A (es) Anticuerpos anti-cd20 y metodos de uso.
EP2311878A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
EP4242236A3 (en) Monoclonal antibodies against claudin-18 for treatment of cancer
NZ595896A (en) Genetic products differentially expressed in tumors and the use thereof
GEP20135917B (en) Stabilized polypeptide compositions
IL196914A (en) Isolated monoclonal antibodies with sequences of different regions that specifically bind il-31, polynucleotide and expression vectors encoding antibodies, methods for their production and use
HUS1300076I1 (hu) Diaril-hidantoin vegyületek
EP1578799B8 (en) Antibodies directed to tumor necrosis factor and uses thereof
EP2046836A4 (en) ANTIBODY BINDING SPECIFICALLY TO DR5 AND COMPOSITION FOR PREVENTING OR TREATING CANCER, AND COMPRISING THE SAME
NZ717213A (en) Anti-pd-l1 antibodies and their use to enhance t-cell function
MX2009012838A (es) Composicion de un primer anticuerpo monoclonal no marcado que se aglutina a un antigeno tumoral y a un segundo anticuerpo monoclonal de reaccion no cruzada marcado con un marcador fluorescsente del infrarrojo proximo.
MXPA05011755A (es) Composiciones y metodos para inmunoterapia especifica de tumor wilms 1.
WO2009067660A3 (en) Anti-factor xi monoclonal antibodies and methods of use thereof
WO2008154249A3 (en) Gene expression markers of tumor resistance to her2 inhibitor treatment
WO2007081720A3 (en) Microrna-based methods and compositions for the diagnosis, prognosis and treatment of lung cancer
WO2004044160A3 (en) Muc1 interference rna compositions and methods derived therefrom
GEP20125629B (en) Novel antiproliferation antibodies
WO2004055513A3 (en) Use of cd137 antagonists for the treatment of tumors
WO2008019326A3 (en) Ephb3-specific antibody and uses thereof
WO2012156975A8 (en) COMBINATIONS OF ANTI ErbB ANTIBODIES FOR THE TREATMENT OF CANCER
IL157464A0 (en) Zinc finger binding domains for nucleotide sequence ann
WO2005023186A3 (en) Methods of identifying agents that inhibit the growth of cancer cells
WO2005017112A3 (en) Methods of inhibiting cancer growth by binding to nuclear receptors

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees